

TEOSYAL RHA® 1 for the Correction of Moderate to Severe Tissue Volume Deficiency in the Infraorbital Region in Chinese Adults

NCT06749587

Status	RECRUITING
Phase	Not Applicable
Sponsor	Teoxane SA
Enrollment	260 participants

Key Eligibility Criteria

Inclusion (7)

- Chinese male and female, 18 years of age or older.
- Subject seeking treatment of moderate to severe tissue volume deficiencies in the infraorbital region.
- Subjects with a grade of 2 (moderate) or 3 (severe) on the TIOHS for both eyes, as determined on assessments by the Treating Investigator (TI) and BLE.
- Subject willing to abstain from all other facial aesthetic procedures/therapies that could interfere with effectiveness evaluations (e.g., dermal fillers outside of this investigation, toxin treatments, facial ablative or fractional laser, Intense Pulsed Light \[IPL], microdermabrasion, chemical peels, skin bleaching agents, non-ablative laser, or energy-based device for skin-tightening, surgical procedures, etc.) during participation in the investigation.
- Woman of childbearing potential agree to use contraception during the investigation.

... and 2 more (see full listing online)

Exclusion (6)

- Known hypersensitivity or previous allergic reaction to any component of the study device.
- Known sensitivity to local anesthetics of the amide type, history of multiple severe allergies, or history of anaphylactic shock.
- History of active chronic debilitating systemic disease that, in the opinion of the investigator, would make the subject a poor candidate in the study.
- History of connective tissue disease.
- Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.

... and 1 more (see full listing online)

Locations (1 total)

Guangdong Second Provincial General Hospital, Guangzhou, China